A performance evaluation study designed to assess the precision and accuracy of the Lumira DX point of care (POC) and C-Reactive (CRP) assay as an aid in the detection and evaluation of infection, tissue injury and inflammatory disorders.
In the emergency department (ED), CRP is tested in patients presenting with a variety of symptoms as an aid the detection and evaluation of infection, tissue injury or inflammatory disorders.
Primary objective – To determine the performance of the LumiraDx POC CRP assay when compared to the Siemens Dimension reference method in patients with symptoms of infection, tissue injury and inflammatory disorders.
Sample size – 50 participants over a duration of approximately 4 weeks.
TARGET CTCA is a joint venture between EMERGE and the cardiology research team aiming to recruit patients with suspected ACS across NHS Lothian and NHS Greater Glasgow and Clyde. The study aims to recruit 2270 participants. For further information, please contact the EMERGE team.
Early diagnosis is central to improving outcomes for patients with cancer. For cancers without specific risk factors, or with no screening programs are difficult to diagnose and patients often present with non-specific symptoms. Unfortunately this means that these patients are often diagnosed late on in the development of the disease and treatment options are reduced.